Skip to main content

UBS Group AG

Position in FTRE — Fortrea Holdings Inc.

CIK 1610520 ZURICH, V8

Position in FTRE

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$5,449,808
+$722,360 QoQ
Shares Held
578,536
+111.1% QoQ
Ownership
0.612%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Jun 2023
12 quarters on record
Voting authority Sole 93.56721102921858.ToString("F0")% Shared 0.ToString("F0")% None 6.432788970781421.ToString("F0")%

Common Shares in FTRE Over Time

Shares Held

Position Value (USD)

Derivatives in FTRE

reported options exposure · as of Jun 30, 2025
CallValue
$0
CallShares
0
PutValue
$1,235,000
PutShares
250,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS Group AG holds $8,306,928,575 across 560 Biotechnology names. FTRE ranks #145 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in FTRE

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $5,449,808 578,536
2025-12-31 $4,727,448 274,055
2025-09-30 $6,908,971 820,543
2025-06-30 $1,235,000 250,000
2025-06-30 $5,871,485 1,188,560
2025-03-31 $3,033,113 401,737
2024-12-31 $7,380,661 395,746
2024-09-30 $1,978,640 98,932
2024-06-30 $2,987,752 128,010
2024-03-31 $6,572,683 163,744
2023-12-31 $4,866,107 139,430
2023-09-30 $107,448,337 3,758,249
2023-06-30 $2,346 69